Total Payments
$679.25
2024 Payments
$288.27
Companies
13
Transactions
23
Medicare Patients
2,452
Medicare Billing
$701,769
Payment Breakdown by Category
Food & Beverage$600.26 (88.4%)
Education$78.99 (11.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $600.26 | 22 | 88.4% |
| Education | $78.99 | 1 | 11.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $120.10 | 1 | $0 (2017) |
| Astellas Pharma US Inc | $113.04 | 5 | $0 (2017) |
| Actelion Pharmaceuticals US, Inc. | $104.65 | 2 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $78.82 | 3 | $0 (2024) |
| Ambu Inc. | $62.95 | 2 | $0 (2024) |
| Insmed, Inc. | $48.94 | 2 | $0 (2024) |
| GlaxoSmithKline, LLC. | $46.89 | 2 | $0 (2024) |
| Boston Scientific Corporation | $34.37 | 1 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $19.03 | 1 | $0 (2023) |
| Allergan Inc. | $15.42 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $288.27 | 9 | Actelion Pharmaceuticals US, Inc. ($104.65) |
| 2023 | $87.64 | 4 | Boehringer Ingelheim Pharmaceuticals, Inc. ($30.70) |
| 2022 | $34.37 | 1 | Boston Scientific Corporation ($34.37) |
| 2017 | $268.97 | 9 | PFIZER INC. ($120.10) |
All Payment Transactions
23 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $27.63 | General |
| 11/07/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: Respiratory | ||||||
| 11/01/2024 | Ambu Inc. | — | Food and Beverage | Cash or cash equivalent | $33.33 | General |
| 08/21/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $24.44 | General |
| Category: Respiratory | ||||||
| 08/09/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Education | In-kind items and services | $78.99 | General |
| Category: Cardiology | ||||||
| 08/01/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $25.66 | General |
| Category: Cardiology | ||||||
| 06/14/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $23.61 | General |
| Category: RESPIRATORY | ||||||
| 06/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $20.49 | General |
| Category: RESPIRATORY | ||||||
| 04/18/2024 | Ambu Inc. | — | Food and Beverage | Cash or cash equivalent | $29.62 | General |
| 12/08/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $23.28 | General |
| Category: RESPIRATORY | ||||||
| 11/22/2023 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $19.03 | General |
| Category: Oncology | ||||||
| 09/06/2023 | bioMerieux Inc | — | Food and Beverage | In-kind items and services | $14.63 | General |
| 06/29/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV | Food and Beverage | In-kind items and services | $30.70 | General |
| 03/04/2022 | Boston Scientific Corporation | EXALT Model D (Device) | Food and Beverage | In-kind items and services | $34.37 | General |
| Category: EXALT_ENDO | ||||||
| 06/06/2017 | Astellas Pharma US Inc | Ambisome (Drug), Lexiscan, Cresemba | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: Infectious Diseases | ||||||
| 05/25/2017 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $9.16 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 04/22/2017 | Astellas Pharma US Inc | Ambisome (Drug), Mycamine, Cresemba | Food and Beverage | In-kind items and services | $24.03 | General |
| Category: Infectious Diseases | ||||||
| 03/23/2017 | Astellas Pharma US Inc | Ambisome (Drug), Lexiscan, Cresemba | Food and Beverage | In-kind items and services | $21.56 | General |
| Category: Infectious Diseases | ||||||
| 03/17/2017 | Merck Sharp & Dohme Corporation | PNEUMOVAX 23 (Biological), ASMANEX, DULERA | Food and Beverage | In-kind items and services | $11.25 | General |
| Category: VACCINE | ||||||
| 02/23/2017 | Astellas Pharma US Inc | Ambisome (Drug), Lexiscan, Cresemba | Food and Beverage | In-kind items and services | $22.43 | General |
| Category: Infectious Diseases | ||||||
| 01/26/2017 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $120.10 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 01/26/2017 | Astellas Pharma US Inc | Ambisome (Drug), Cresemba, Mycamine | Food and Beverage | In-kind items and services | $21.70 | General |
| Category: Infectious Diseases | ||||||
| 01/04/2017 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $15.42 | General |
| Category: ANTI-INFECTIVE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 609 | 1,393 | $637,423 | $204,517 |
| 2022 | 8 | 705 | 1,604 | $500,860 | $167,154 |
| 2021 | 8 | 585 | 1,497 | $446,708 | $177,529 |
| 2020 | 6 | 553 | 1,335 | $382,467 | $152,568 |
Total Patients
2,452
Total Services
5,829
Medicare Billing
$701,769
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 266 | 652 | $397,720 | $127,979 | 32.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 143 | 424 | $144,840 | $45,982 | 31.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 91 | 190 | $41,800 | $13,728 | 32.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 39 | 40 | $20,100 | $6,330 | 31.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 45 | 46 | $17,383 | $5,501 | 31.6% |
| 31622 | Diagnostic exam of lung airway using an endoscope | Facility | 2023 | 25 | 41 | $15,580 | $4,999 | 32.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 177 | 553 | $160,370 | $53,462 | 33.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 105 | 222 | $139,860 | $47,023 | 33.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 195 | 584 | $116,800 | $39,262 | 33.6% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 108 | 116 | $34,800 | $11,361 | 32.6% |
| 31622 | Diagnostic exam of lung airway using an endoscope | Facility | 2022 | 38 | 44 | $17,160 | $5,654 | 32.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 41 | 41 | $15,990 | $5,313 | 33.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 23 | 24 | $13,680 | $4,336 | 31.7% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 18 | 20 | $2,200 | $744.36 | 33.8% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 141 | 333 | $173,160 | $70,875 | 40.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 170 | 516 | $124,872 | $50,497 | 40.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 128 | 468 | $79,092 | $32,007 | 40.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 55 | 69 | $22,011 | $9,002 | 40.9% |
| 31622 | Diagnostic examination of lung airways using an endoscope | Facility | 2021 | 34 | 50 | $23,750 | $6,482 | 27.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 30 | 31 | $14,632 | $5,912 | 40.4% |
| 32551 | Removal of fluid from between lung and chest cavity, open procedure | Facility | 2021 | 13 | 13 | $7,644 | $2,137 | 28.0% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 14 | 17 | $1,547 | $616.93 | 39.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 229 | 762 | $184,404 | $74,070 | 40.2% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 120 | 208 | $108,160 | $43,886 | 40.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 114 | 261 | $44,109 | $17,628 | 40.0% |
About Dr. Chanaka Seneviratne, MD
Dr. Chanaka Seneviratne, MD is a Critical Care Medicine healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1558474619.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Chanaka Seneviratne, MD has received a total of $679.25 in payments from pharmaceutical and medical device companies, with $288.27 received in 2024. These payments were reported across 23 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($600.26).
As a Medicare-enrolled provider, Seneviratne has provided services to 2,452 Medicare beneficiaries, totaling 5,829 services with total Medicare billing of $701,769. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Pulmonary Disease
- Location Brooklyn, NY
- Active Since 08/15/2006
- Last Updated 09/11/2025
- Taxonomy Code 207RC0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1558474619
Products in Payments
- ELIQUIS (Drug) $120.10
- Ambisome (Drug) $113.04
- OPSUMIT (Drug) $78.99
- Arikayce (Drug) $48.94
- TRELEGY ELLIPTA (Drug) $46.89
- EXALT Model D (Device) $34.37
- UPTRAVI (Drug) $25.66
- OFEV (Drug) $20.49
- OPDUALAG (Drug) $19.03
- AVYCAZ (Drug) $15.42
- PNEUMOVAX 23 (Biological) $11.25
- LifeVest (Device) $9.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Critical Care Medicine Doctors in Brooklyn
Dr. Joshua Rosenberg, M.d, M.D
Critical Care Medicine — Payments: $893,165
Critical Care Medicine $893,165
Dr. Aaliya Burza, M.d, M.D
Critical Care Medicine — Payments: $54,441
Critical Care Medicine $54,441
Dr. Keerthana Keshava, M.b.b.s, M.B.B.S
Critical Care Medicine — Payments: $23,722
Critical Care Medicine $23,722
Dr. Yizhak Kupfer, Md, MD
Critical Care Medicine — Payments: $22,120
Critical Care Medicine $22,120
Mediha Ibrahim, M.d, M.D
Critical Care Medicine — Payments: $14,961
Critical Care Medicine $14,961
Igor Chernyavskiy, M.d, M.D
Critical Care Medicine — Payments: $7,598
Critical Care Medicine $7,598